Recent Updates
Recently added Catalysts

BMS-986527

Phase 1

Clear Cell Renal Cell Carcinoma (ccRCC) | Small Molecules | Oncology |Bristol-Myers Squibb Company|Trials Updated: Sep 30, 2026

BMS-986527 development status

Highest phase Phase 1
Registered trials 1 across 1 sponsor since Sep 2026

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

CONTROLLED
Total Trials1
Total Enrollment112

FDA Designations

No designations recorded

BMS-986527 clinical trials

BMS-986527 · 1 trial · 1 indication

Phase 1 1
NCT07848295A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)Clear Cell Renal Cell Carcinoma (ccRCC)
NOT YET_RECRUITING112 Analytics
PHASE1NOT YET_RECRUITING
A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Clear Cell Renal Cell Carcinoma (ccRCC)Unlock trial analytics

Study Endpoints

Primary Endpoints

Incidence of adverse events (AEs)
Up to 2 years
Incidence of serious adverse events (SAEs)
Up to 2 years
Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria
Up to 2 years
Incidence of AEs leading to discontinuation
Up to 2 years
Number of deaths
Up to 2 years

Secondary Endpoints

Overall response rate (ORR)
Up to 2 years
Complete response rate (CRR)
Up to 2 years
Disease control rate (DCR)
Up to 2 years
Unlock Study Endpoints

Study Design & Arms

AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Cohort 1: BMS-986527 monotherapyEXPERIMENTAL -
Cohort 2: BMS-986527 with NivolumabEXPERIMENTAL -
Cohort 3: BMS-986527 with CabozantinibEXPERIMENTAL -

Interventions

NameTypeDescription
BMS-986527DRUGSpecified dose on specified days
NivolumabDRUGSpecified dose on specified days
CabozantinibDRUGSpecified dose on specified days
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites17

Inclusion Criteria * Participants must have a histologically confirmed diagnosis of a locally advanced and unresectable or metastatic renal cell carcinoma (RCC) with clear cell component. * Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Participa...

Countries:United StatesBelgiumFranceGermanyItalyNetherlandsSpain
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWSep 30, 2026NCT07848295NEW_TRIAL: changed
LOWSep 30, 2026NCT07848295NEW_TRIAL: changed

Frequently asked questions about BMS-986527

What is BMS-986527?

BMS-986527 is an investigational small molecule being developed by Bristol-Myers Squibb for clear cell renal cell carcinoma (ccRCC), a form of kidney cancer. It is in Phase 1 clinical development and has not been approved for any use. It is being studied as a potential treatment for patients with this cancer type.

What is BMS-986527 used for?

BMS-986527 is being studied for the treatment of clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. It is an investigational therapy in Phase 1 testing, so it is not yet available as a treatment outside of clinical trials. Its use in ccRCC remains under evaluation.

Who makes BMS-986527?

BMS-986527 is being developed by Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY. Bristol-Myers Squibb is the sponsor of the clinical program evaluating the drug in clear cell renal cell carcinoma.

What phase is BMS-986527 in?

BMS-986527 is in Phase 1 clinical development. It is an investigational small molecule and has not been approved by the FDA or any other regulatory agency. The Phase 1 program is designed to assess safety and tolerability in participants with clear cell renal cell carcinoma.

What clinical trials is BMS-986527 in?

BMS-986527 is being evaluated in one clinical trial, NCT07848295, titled A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC). The Phase 1 trial is not yet recruiting and plans to enroll 112 participants across the United States, Belgium, France, Germany, Italy, Netherlands, and Spain.

Who can enroll in the BMS-986527 trial?

The Phase 1 trial NCT07848295 enrolls adults 18 years and older of all sexes with clear cell renal cell carcinoma. It does not accept healthy volunteers. The study is a controlled trial and is not yet recruiting, with a planned enrollment of 112 participants across seven countries.